2484919-71-1

RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research[1].

EGFR: 56.78 ± 4. μM (IC₅₀); Aurora A: 0.242 ± 0. μM (IC₅₀); Aurora B: 0.536 ± 45 μM (IC₅₀); MAP4K4: 3.428 ± 0. μM (IC₅₀)

[1] Lakkaniga NR, et al. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Nov 15;206:112691. DOI:10.1016/j.ejmech.2020.112691